Categories AlphaGraphs, Earnings, Health Care
Everything you need to know about Biogen’s (BIIB) Q1 2023 earnings
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the first quarter of 2023.
Total revenue declined 3% year-over-year to $2.46 billion. For the full year of 2023, the company expects revenues to decline in the mid-single digit percentage and projects adjusted earnings per share in the range of $15.00 to 16.00.
Net income attributable to Biogen Inc. was $387.9 million or $2.67 per share in Q1, compared to $303.8 million or $2.06 per share last year. Adjusted earnings declined 6% to $3.40 per share.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Docusign (DOCU) Earnings: 4Q25 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported total revenue of $776.3 million for the fourth quarter of 2025, up 9% year-over-year. Net income was $83.5 million, or $0.39 per share, compared to
DG Q4 Call Highlights: Consumer Shifts, Inventory Wins, and Rural Delivery Boom!
Dollar General Corp., a retailer that operates discount stores, in its Q4 earnings call discussed Dollar General's financial strategy to reach 6-7% operating margins by 2028 through shrink reduction, inventory
ULTA Earnings: Highlights of Ulta Beauty’s Q4 2024 results
Ulta Beauty, Inc. (NASDAQ: ULTA), a leading retailer of cosmetics and personal care products, on Thursday reported a decrease in net sales for the fourth quarter of 2024. Fourth-quarter net
